Latest Content

A novel form of agomelatine shows positive initial results.

Phase 2 trial of oveporexton for narcolepsy type 1 finds improvement on measures of cognition, in addition to previously demonstrated improved hallmark symptom of nighttime wakefulness.

Lipocine's oral brexanolone (LPCN 1154) for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial.

Pop psychiatry fuels misdiagnosis of autism or ADHD, delaying psychosis and bipolar treatment—why accurate labels and early meds save lives.

Yesterday, we launched a spaceship the moon for the first time in 53 years. What implications does this journey have for psychiatry?

An interview with Felice Jacka, OAM, PhD, on the rapidly developing field of nutritional psychiatry.

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Explore fresh clinical insights on schizophrenia—mortality, stigma, cannabis links, lifestyle, and new treatments—and share cases for our April series.

Q1 psychiatric pipeline shifts: wins, setbacks, and standout trials in depression, schizophrenia, Alzheimer disease, and narcolepsy—what to watch next.

Being a fool can run from being thought to be inappropriately silly to Shakespeare’s fools of creative wisdom. Where does psychiatry come in?

Elite coaches often run on severe sleep loss, risking impaired decisions, emotion control, and leadership.

Continuity vs discontinuity, tradition vs change in the “psy disciplines.”

Check out the pipeline updates from March!